While all three medications are GLP-1 agonists, there are key differences:
Active Ingredients: Zepbound contains tirzepatide, a dual agonist that targets both GIP and GLP-1 receptors. Ozempic and Wegovy contain semaglutide, which targets only the GLP-1 receptor.
FDA Approval: Zepbound and Wegovy are approved specifically for weight loss. Ozempic is approved for type 2 diabetes but is often used off-label for weight loss.